16.07.2015 • NewsBioprinting3D printingPoietis

BASF and Poietis to Jointly Research Bioprinting

BASF has agreed to cooperate with French biotech firm Poietis to try to improve skin treatment with the use of 3D printing. The French company has pioneered a method of laser-assisted bioprinting said to enable scientists to reproduce organic tissue.

The technology will allow BASF to print skin cells in three-dimensional patterns within its Mimeskin skin equivalent material, which the German chemical giant said is the closest equivalent to the original physiological tissue of human skin.

“Compared to other bioprinting methods the laser-assisted technology provides higher resolution when it comes to the patterning of cells,” said Sebastien Cadau, head of BASF's tissue engineering development.

Poietis' bioprinting method will be the first step in enabling automatic reproduction of Mimeskin and could eventually lead to more advanced models with other types of cells, the companies said.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Digital Validation
Transforming from Paper to Digital

Digital Validation

Our experts will delve into the recently released International Society for Pharmaceutical Engineering (ISPE) Good Practice Guide: Digital Validation